This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

W. W. Tourtellotte, MD, PhD; K. Syndulko, PhD; A. R. Potvin, PhD; S. B. Hirsch, MD; J. H. Potvin, PhD

Arch Neurol. 1980;37(11):723-726.

Abstract
• A randomized, double-blind clinical trial was designed to compare two ratios of carbidopa to levodopa (10 mg of carbidopa to 100 mg of levodopa [Sinemet 10/100] and 20 mg of carbidopa to 100 mg of levodopa [Sinemet 20/100]) with levodopa (100 mg) alone. Twenty-nine male patients (46 to 78 years of age) with clinically definite idiopathic Parkinson's disease of mild to moderate severity were selected and hospitalized for the threeweek period of the study. Medications being taken at time of entry were phased out during week 1. Fixed daily increments of medications were given during week 2, and adjusted during week 3 to achieve best clinical response with fewest side effects. Qualitative and quantitative examinations of neurologic function showed that upper extremity measurements of resting tremor, rigidity, and finger-tapping speed, and lower extremity measurements of foot coordination and tandem gait (both types of speed tests) showed significantly more improvement in patients receiving the 20:100 combination than in those receiving the 10:100 combination or levodopa alone. Adverse effects were similar and minimal in each of the three groups. Results indicate that increasing the amount of carbidopa from 10 to 20 mg per 100-mg dose of levodopa gives a greater therapeutic response in Parkinson's disease than does a 10:100 carbidopa-levodopa ratio or levodopa alone.

Author Affiliations
From the Neurology and Research Services, VA Wadsworth Medical Center (Drs Tourtellotte, Syndulko, and Hirsch), and the Department of Neurology, University of California School of Medicine (Dr Tourtellotte), Los Angeles, and the Biomedical Engineering Program (Dr A. Potvin) and the Department of English (Dr J. Potvin), the University of Texas at Arlington.

Footnotes
Accepted for publication Jan 19, 1980.

Reprint requests to Neurology Service, VA Wadsworth Medical Center, Wilshire and Sawtelle Blvds, Los Angeles, CA 90073 (Dr Tourtellotte).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Levodopa/carbidopa/entacapone (Stalevo)
Hauser
Neurology 2004;62:S64-71.
ABSTRACT | FULL TEXT